Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries.
Leblebicioglu H, Arama V, Causse X, Marcellin P, Ozaras R, Postawa-Klozinska B, Simon K, Suceveanu AI, Wiese M, Zeuzem S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zarski JP; AI463-121 European Longitudinal Chronic Hepatitis B Study Group. Leblebicioglu H, et al. J Viral Hepat. 2014;21(9):662-70. doi: 10.1111/jvh.12202. Epub 2013 Dec 15. J Viral Hepat. 2014. PMID: 24329883
Hepatitis E virus infection in Turkey: a systematic review.
Leblebicioglu H, Ozaras R. Leblebicioglu H, et al. Ann Clin Microbiol Antimicrob. 2018 May 2;17(1):17. doi: 10.1186/s12941-018-0269-6. Ann Clin Microbiol Antimicrob. 2018. PMID: 29716597 Free PMC article. Review.
How to compare antivirals in the treatment of chronic hepatitis B?
Ozaras R, Leblebicioglu H. Ozaras R, et al. Among authors: leblebicioglu h. Ann Clin Microbiol Antimicrob. 2009 Mar 2;8:6. doi: 10.1186/1476-0711-8-6. Ann Clin Microbiol Antimicrob. 2009. PMID: 19254373 Free PMC article. No abstract available.
Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study.
Marcellin P, Arama V, Leblebicioglu H, Zarski JP, Zeuzem S, Mauss S, Sieklucki J, Acalovschi M, Usluer G, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Simon K; AI463-121 European Longitudinal Chronic Hepatitis B Study Group. Marcellin P, et al. Among authors: leblebicioglu h. Antivir Ther. 2014;19(3):235-43. doi: 10.3851/IMP2573. Epub 2013 Apr 10. Antivir Ther. 2014. PMID: 23574686
Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
Arama V, Leblebicioglu H, Simon K, Zarski JP, Niederau C, Habersetzer F, Vermehren J, Bludzin W, Jinga M, Ulusoy S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zeuzem S; AI463-121 European Longitudinal Chronic Hepatitis B Study Group. Arama V, et al. Among authors: leblebicioglu h. Antivir Ther. 2014;19(3):245-57. doi: 10.3851/IMP2719. Epub 2013 Dec 17. Antivir Ther. 2014. PMID: 24343051
Syrian refugees and infectious disease challenges.
Leblebicioglu H, Ozaras R. Leblebicioglu H, et al. Travel Med Infect Dis. 2015 Nov-Dec;13(6):443-4. doi: 10.1016/j.tmaid.2015.11.007. Travel Med Infect Dis. 2015. PMID: 26701858 No abstract available.
Medical Considerations before International Travel.
Ozaras R, Leblebicioglu H. Ozaras R, et al. Among authors: leblebicioglu h. N Engl J Med. 2016 Oct 13;375(15):e32. doi: 10.1056/NEJMc1610671. N Engl J Med. 2016. PMID: 27732816 No abstract available.
Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe.
Ozaras R, Corti G, Ruta S, Lacombe K, Mondelli MU, Irwing WL, Puoti M, Khalighi A, Santos ML, Harxhi A, Lazarevic I, Soriano V, Gervain J, Leblebicioglu H, Salmon D, Arends JE; ESCMID Study Group for Viral Hepatitis. Ozaras R, et al. Among authors: leblebicioglu h. Clin Microbiol Infect. 2015 Nov;21(11):1027-32. doi: 10.1016/j.cmi.2015.07.002. Epub 2015 Jul 10. Clin Microbiol Infect. 2015. PMID: 26166544 Free article.
169 results